open access

Vol 24, No 1 (2020)
CASE REPORT
Published online: 2020-01-22
Get Citation

Epic battles in endocrinology — malignant pheochromocytoma: a case report

Elżbieta Zych, Aleksandra Jaruszewska, Łukasz Obołończyk, Piotr Wiśniewski, Krzysztof Sworczak, Katarzyna Chełmińska, Jarosław Ćwikła
DOI: 10.5603/AH.a2020.0001
·
Arterial Hypertension 2020;24(1):38-44.

open access

Vol 24, No 1 (2020)
CASE REPORT
Published online: 2020-01-22

Abstract

The rarity of malignant pheochromocytoma coupled with the lack of definitive predictors of malignancy and the variability of clinical course, poses a significant diagnostic and therapeutic challenge. Since data on treatment is so scarce, case reports are a valuable source of knowledge for clinicians. This case report describes the medical history of a woman, aged 51 at the time of initial diagnosis and adrenalectomy.

Within over 5 years she presented with recurrent relapse of tumour in adrenal gland bed and multiple distant metastases to descending colon, abdominal wall, postoperative scars, and the peritoneum. Neither before diagnosis nor during the whole follow-up were symptoms associated with pheochromocytoma present.

The treatment administered to our patient consisted of numerous debulking surgeries along with administration of both hot and cold somatostatin analogues. We believe that debulking surgeries played a substantial role in enabling the patient to survive nearly 6 years despite aggressive clinical course of pheochromocytoma. She passed away in 2012 as a result of postlaparotomy complications.

We stress the role of debulking surgery in the treatment of malignant pheochromocytoma and summarise current
literature.

Abstract

The rarity of malignant pheochromocytoma coupled with the lack of definitive predictors of malignancy and the variability of clinical course, poses a significant diagnostic and therapeutic challenge. Since data on treatment is so scarce, case reports are a valuable source of knowledge for clinicians. This case report describes the medical history of a woman, aged 51 at the time of initial diagnosis and adrenalectomy.

Within over 5 years she presented with recurrent relapse of tumour in adrenal gland bed and multiple distant metastases to descending colon, abdominal wall, postoperative scars, and the peritoneum. Neither before diagnosis nor during the whole follow-up were symptoms associated with pheochromocytoma present.

The treatment administered to our patient consisted of numerous debulking surgeries along with administration of both hot and cold somatostatin analogues. We believe that debulking surgeries played a substantial role in enabling the patient to survive nearly 6 years despite aggressive clinical course of pheochromocytoma. She passed away in 2012 as a result of postlaparotomy complications.

We stress the role of debulking surgery in the treatment of malignant pheochromocytoma and summarise current
literature.

Get Citation

Keywords

malignant pheochromocytoma; debulking surgery; case report; lanreotide

About this article
Title

Epic battles in endocrinology — malignant pheochromocytoma: a case report

Journal

Arterial Hypertension

Issue

Vol 24, No 1 (2020)

Pages

38-44

Published online

2020-01-22

DOI

10.5603/AH.a2020.0001

Bibliographic record

Arterial Hypertension 2020;24(1):38-44.

Keywords

malignant pheochromocytoma
debulking surgery
case report
lanreotide

Authors

Elżbieta Zych
Aleksandra Jaruszewska
Łukasz Obołończyk
Piotr Wiśniewski
Krzysztof Sworczak
Katarzyna Chełmińska
Jarosław Ćwikła

References (28)
  1. Lenders JWM, Duh QY, Eisenhofer G, et al. Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(6): 1915–1942.
  2. Wan WH, Tan KY, Ng C, et al. Metastatic malignant phaeochromocytoma: A rare entity that underlies a therapeutic quandary. Asian J Surg. 2006; 29(4): 294–302.
  3. Baudin E, Habra MA, Deschamps F, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014; 171(3): R111–R122.
  4. Giubellino A, Sourbier C, Lee MJ, et al. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One. 2013; 8(2): e56083.
  5. Sołtysiak M, Gołofit P, Łokaj M, et al. Biochemically silent pheochromocytoma — rare, but not uncommon. Case study. Art Hyperten. 2015; 19(4): 200–202.
  6. Januszewicz W, Jarząb B, Januszewicz A, et al. Malignant pheochromocytoma. Nadciśnienie Tętnicze. 2005; 9(2): 132–140.
  7. Yu J, Pacak K. Management of Malignant Pheochromocytoma. The Endocrinologist. 2002; 12(4): 291–299.
  8. Adjallé R, Plouin PF, Pacak K, et al. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009; 41(9): 687–696.
  9. Zukauskaite R, Hjorthgau K, Poulsen PL, et al. Malignant pheochromocytoma and paraganglioma: three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs. Acta Oncol. 2011; 50(8): 1255–1259.
  10. Tanabe A, Naruse M, Nomura K, et al. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer. 2013; 4(2): 103–110.
  11. Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008; 113(8): 2020–2028.
  12. Watanabe D, Tanabe A, Naruse M, et al. Transcatheter arterial embolization for the treatment of liver metastases in a patient with malignant pheochromocytoma. Endocr J. 2006; 53(1): 59–66.
  13. Kim JK, Kim BH, Baek SM, et al. Incidentally detected inoperable malignant pheochromocytoma with hepatic metastasis treated by transcatheter arterial chemoembolization. Endocrinol Metab (Seoul). 2014; 29(4): 584–589.
  14. Edström Elder E, Hjelm Skog AL, Höög A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol. 2003; 29(3): 278–283.
  15. Jimenez C, Rohren E, Habra MA, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013; 15(4): 356–371.
  16. Babinska A, Peksa R, Sworczak K. Primary malignant lymphoma combined with clinically "silent" pheochromocytoma in the same adrenal gland. World J Surg Oncol. 2015; 13: 289.
  17. Januszewicz W, Prejbisz A, Januszewicz A, et al. Pheochromocytoma — Disease that Can Stimulate Many Different Syndromes. Nadciśnienie Tętnicze. 2002; 6(3): 217 –228.
  18. López-Gómez J, Salazar-Álvarez MaA, Adame RY, et al. Metastatic pheochromocytoma to liver without elevation of metanephrines and catecholamines. Int J Surg Case Rep. 2016; 29: 71–75.
  19. Arnas-Leon C, Sánchez V, Santana Suárez AD, et al. Complete Remission in Metastatic Pheochromocytoma Treated with Extensive Surgery. Cureus. 2016; 8(1): e447.
  20. Favier J, Igaz P, Burnichon N, et al. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol. 2012; 23(1): 34–42.
  21. Sun FK, He HC, Su TW, et al. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma. Chin Med J (Engl). 2012; 125(12 ): 2231–2234.
  22. Hata J, Haga N, Ishibashi K, et al. Sunitinib for refractory malignant pheochromocytoma: two case reports. Int Urol Nephrol. 2014; 46(7): 1309–1312.
  23. Rose B, Matthay KK, Price D, et al. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer. 2003; 98(2): 239–248.
  24. Rutherford MA, Rankin AJ, Yates TM, et al. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre. QJM. 2015; 108(5): 361–368.
  25. Lam MG, Lips CJM, Jager PL, et al. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma. J Clin Endocrinol Metab. 2005; 90(10): 5888–5895.
  26. Gedik GK, Hoefnagel CA, Bais E, et al. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008; 35(4): 725–733.
  27. Chrisoulidou A, Kaltsas G, Ilias I, et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007; 14(3): 569–585.
  28. Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, et al. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf). 2002; 57(5): 629–634.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl